NCT06066606View on ClinicalTrials.gov

U-LABA/ICS Effects on Exercise Performance, Vilanterol

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 3, 2023

Primary Completion Date

July 15, 2026

Study Completion Date

December 1, 2026

Conditions
Exercise Performance
Interventions
DRUG

Vilanterol and Fluticasone Furoate (low dose)

Participants are administered 25 µg of vilanterol + fluticasone furoate

DRUG

Vilanterol and Fluticasone Furoate (high dose)

Participants are administered 100 µg of vilanterol + fluticasone furoate

DRUG

Placebo

Participants are administered placebo

Trial Locations (1)

2100

RECRUITING

August Krogh Building, Copenhagen

All Listed Sponsors
lead

Morten Hostrup, PhD

OTHER